A lab linked to Bill Gates is creating a synthetic version of monkeypox that is 1,000 times more deadly than the natural version.
House Energy and Commerce Committee Chair Cathy McMorris Rogers (R-WA), Health Care Subcommittee Chairman Brett Guthrie (R-KY) and Oversight and Investigations Subcommittee Chairman Morgan Griffith (R-VA) today sent a letter to Lawrence Tabak, acting senior official director of the NIH, regarding details of a dangerous monkeypox experiment planned by an NIH-Gates-funded researcher.
Strangesounds.org reports: The letter follows a letter dated October 31, 2022, to which the NIH has not released an official response. It also contains a formal notice of retention of all existing and future records and materials related to the case.
The project in question involves transferring genes from “clade 1” or the monkeypox virus (a rare version of the monkeypox virus that is 1,000 times more lethal in mice than the version currently circulating in humans) to “clade 2” or the West African clade of monkeypox. (the version currently circulating among people). circulates among people). The Clade 1 version of the monkeypox virus is so dangerous that it is classified as a federally designated pathogen. Information about the specific experiments became known when the researcher discussed his plans in a September 2022 scientific article about the National Institute of Allergy and Infectious Diseases (NIAID) work on monkeypox.
KEY DATA:
“Based on the available information, it seems reasonable to expect that the project will produce a laboratory-created monkeypox virus that is 1,000 times more lethal to mice than the monkeypox virus currently circulating in humans and that is transmitted as efficiently as the monkeypox virus currently circulating in people.” circulates in people. The risk-benefit ratio indicates potentially serious risks with no clear civilian practical application. Accordingly, this experiment appears to involve risks reasonably expected to be created, transmitted, or used by PPPs arising from increased transmissibility or virulence of pathogens in humans. So, under the given circumstances,
“Furthermore, human disease associated with clade 2 or West African monkeypox virus is less severe and associated with less than one percent mortality, while clade 1 or Congo Basin monkeypox infection has a 10 percent mortality rate in unvaccinated individuals. Because of its significantly higher mortality , clade 1, or Congo Basin monkeypox viruses are regulated as selected agents of the Federal Selective Agent Program. Entities possessing, using, or transferring this agent must comply with the HHS Select Agents and Toxins Regulations unless an applicable exemption or exclusion exists. Therefore, under these regulations, the clade 1 monkeypox trial appears to be a limited trial that must be reviewed by the Federal Select Agent Program,
In light of these concerns about the adequacy of NIH’s oversight of research that poses a significant risk to biosafety and biosecurity risks and that involves a federally selected agent, the President requested a formal response by April 13, 2023.
